<DOC>
	<DOCNO>NCT00025584</DOCNO>
	<brief_summary>PS-341 may stop growth tumor cell block enzymes necessary cancer cell growth . Phase II trial study effectiveness PS-341 treat woman metastatic breast cancer</brief_summary>
	<brief_title>PS-341 Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine efficacy PS-341 , term response rate , woman metastatic breast cancer . SECONDARY OBJECTIVES : I . Determine clinical activity drug , term progression-free survival , woman . II . Determine toxicity profile tolerability drug woman . III . Determine pharmacodynamics drug woman . OUTLINE : Patients receive PS-341 IV 3-5 second twice weekly week 1 2 . Courses repeat every 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A maximum 12-35 patient accrue study within 9-12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast cancer Clinical and/or radiological evidence stage IV disease Relapsed resistant disease within 612 month completion prior chemotherapy doxorubicin epirubicin and/or paclitaxel docetaxel foradvanced disease adjuvant setting At least 1 unidimensionally measurable lesion At least 20 mm conventional technique At least 10 mm spiral CT scan No bone metastases measurable site Pleural peritoneal effusion acceptable measurable disease No known brain metastases Hormone receptor status : Estrogen receptornegative Estrogen receptorpositive Female Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST ALT great 2.5 time upper limit normal Creatinine normal Creatinine clearance least 60 mL/min No acute ischemia significant conduction abnormality EKG No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia LVEF great 50 % No uncontrolled concurrent illness No psychiatric illness social situation would preclude study No ongoing active infection No prior allergic reaction ( ) compound similar chemical biologic composition PS341 No malignancy within past 5 year except carcinoma situ cervix basal cell skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective barriermethod contraception See Chemotherapy See Disease Characteristics No 1 prior chemotherapy regimen metastatic disease Highdose regimen bone marrow transplantation consider 1 prior regimen At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior hormonal therapy metastatic disease adjuvant setting allow Prior localized radiotherapy allow influence signal evaluable lesion At least 4 week since prior radiotherapy recover At least 2 week since prior minor surgery recover At least 4 week since prior major surgery recover No concurrent investigational agent No concurrent investigational commercial agent therapy treat malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>